Drug Type Trispecific killer cell engager (TriKE) |
Synonyms |
Target |
Mechanism BCMA inhibitors(B-cell maturation protein inhibitors), CD16a modulators(Low affinity immunoglobulin gamma Fc region receptor III-A modulators), NKp46 agonists(Natural cytotoxicity triggering receptor 1 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | FR | - | |
Neoplasms | Preclinical | FR | - |